ArticleBiomimetics (Basel, Switzerland)2026
Embrace Disorder as a Function: Bio-Informed Biomaterials Design Advanced by Intrinsically Disordered Proteins.
Article in Biomimetics (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
The "lock and key" model of molecular recognition, anchored by the canonical sequence-structure-function paradigm, has successfully served as a basis for designing biomimetic biomaterials for decades. This classical concept associates the function of molecules with a stable three-dimensional structure that recognizes a specific complementary surface. However, biological systems routinely achieve specificity, adaptability, and multifunctionality through protein domains that never adopt a single stable fold. Intrinsically Disordered Proteins (IDPs) and Intrinsically Disordered Regions (IDRs) represent an underutilized functional repertoire in which conformational plasticity, short linear motifs, and phase-separation capacity underpin behaviors that rigid-fold proteins cannot replicate. This Perspective Article extends the molecular biomimetic design framework to the broader range of IDPs/IDRs roles-as effectors triggering downstream signaling, as motion-directing elements interacting with external partners, and as molecular assemblers that organize dynamic complexes while largely avoiding the steric constraints that structured proteins impose. Sequence plasticity, which is greater in disordered domains than in structured proteins, further expands this versatility. Metamorphic and moonlighting proteins further extend the sequence-to-function landscape by encoding multiple folds or functions within a single chain. We discuss how this bio-informed framework guides peptide-based biomaterials design by exploiting the dynamic, multivalent interactions of IDPs. Artificial Intelligence (AI)-guided approaches and machine learning strategies-from supervised classifiers to reinforcement learning loops-that are integrated with experimental feedback to navigate within these high-dimensional design landscapes of intrinsically disordered bio-informed materials systems are provided. Next-generation bio-informed material design must meet challenges driven by clinical, environmental, and industrial needs. Expanding protein matrix in bio-informed material design may enable mimicking complex, dynamic and hierarchical biological functions and materials that are found in Nature. Embracing disorder may even expand functions beyond addressing current challenges. Moving beyond the single-structure paradigm that has dominated the biomimetic field, embracing disorder in biological protein repertoire may give rise to emerging functions in bio-informed biomaterials. These functions are truly adaptive, modular, resourceful, responsive, and sustainable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.